January 2019 in “Figshare” Intralesional corticosteroids are best for mild alopecia areata, and DPCP is best for severe cases.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
December 2024 in “Journal of the European Academy of Dermatology and Venereology” Sublingual and oral minoxidil are equally effective for hair growth, but sublingual causes fewer palpitations.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
6 citations
,
December 1997 in “Journal of The American Academy of Dermatology” CTE can distort results in hair growth trials, so exclude it carefully.
April 2015 in “Reactions Weekly” Finasteride toxicity information is limited, poor quality, and biased.
3 citations
,
September 2022 in “Archives of dermatological research” The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
November 2023 in “The Journal of Urology” The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.
January 2016 in “Surgical and Cosmetic Dermatology” Antifungal treatment reduced asthma exacerbations and corticosteroid use but its overall benefit is unclear.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
August 2021 in “The Journal of Urology” Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
March 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
January 2025 in “Investigative and Clinical Urology” SHPro® improved urinary symptoms and erectile function in men and is safe.
9 citations
,
January 2024 in “International Journal of Dermatology”
1 citations
,
January 2016 in “ARC Journal of Urology” Thermobalancing therapy is safe and effective for treating enlarged prostates.
April 2013 in “Dermatology and therapy” Crescina treatment improves hair resistance and reduces hair loss.
June 2024 in “Dermatology and Therapy” Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
1 citations
,
January 2021 in “medRxiv (Cold Spring Harbor Laboratory)” The study concludes that the new clinical scoring system is a quick, low-cost, and accurate method for diagnosing COVID-19.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
May 2025 in “UNESP Institutional Repository (São Paulo State University)” The 5 mg dose of oral minoxidil is not more effective than the 2.5 mg dose for treating male hair loss.
1 citations
,
January 2012 in “Zhongguo shiyan fangjixue zazhi” Kang'ai injection with FLO chemotherapy improves effectiveness and quality of life in advanced gastric cancer patients.
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
December 2024 in “Frontiers in Neurology” Testosterone with finasteride improved muscle and bone health in men with spinal cord injury.
3 citations
,
March 2021 in “Journal of the European Academy of Dermatology and Venereology” The letter is skeptical about the effectiveness of anti-androgen therapy for COVID-19 and calls for strong evidence from clinical trials.